Entera Bio Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$ENTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16, 2025
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification) |
(Address of principal executive offices) (Zip Code)
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), held its 2025 Annual Meeting of Shareholders on July 16, 2025 (the “Annual Meeting”). The final voting
results for the proposals submitted to a vote of the Company’s shareholders at the Annual Meeting are as follows:
Proposal 1: Election of Haya Taitel to the Board of Directors of the Company for a three-year term to hold office until the Company’s
2028 Annual Meeting of Shareholders or until her successor is elected:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
17,288,920
|
3,069,140
|
137,907
|
6,197,026
|
Proposal 2: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the
Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) filed with the Securities and Exchange Commission on June 5, 2025, in connection
with the Annual Meeting, relating to Ms. Miranda Toledano, the Company’s Chief Executive Officer and a Director:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
19,524,783
|
428,993
|
542,191
|
6,197,026
|
Proposal 3: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy
Statement, relating to Dr. Gregory Burshtein, the Company’s Chief of Research & Development:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
16,518,134
|
3,435,638
|
542,195
|
6,197,026
|
Proposal 4: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy
Statement, relating to Ms. Dana Yaacov-Garbeli, the Company’s Chief Financial Officer:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
19,524,779
|
428,993
|
542,195
|
6,197,026
|
Proposal 5: Ratification and approval of the Company’s amended and restated compensation policy for the directors and officers of the
Company, as described in the Proxy Statement:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
19,520,049
|
432,623
|
543,295
|
6,197,026
|
Proposal 6: Ratification and approval, on an advisory, non-binding basis, of the compensation of the Company’s named executive
officers, as described in the Proxy Statement:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
19,508,920
|
443,752
|
543,295
|
6,197,026
|
Proposal 7: Ratification and approval of Kesselman &
Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2025, and authorization of the Company’s Board of Directors, or the Audit Committee, if authorized by the Board of Directors, to determine the compensation of the auditors in accordance with the volume
and nature of their services, as described in the Proxy Statement:
|
Votes
|
Votes
|
Broker
|
||||
|
For
|
Against
|
Abstentions
|
Non-Votes
|
|||
|
26,617,578
|
59,966
|
15,449
|
0
|
No other matters were considered or voted upon at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
|
ENTERA BIO LTD.
|
||
|
Date: July 18, 2025
|
By:
|
/s/ Miranda Toledano
|
|
Name: Miranda Toledano
Title: Chief Executive Officer
|